

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 02D1036810	(X3) Date Survey Completed 04/08/2023
Name of Provider or Supplier Nick Sarrimanolis Md Llc	Street Address, City, State 1867 Airport Way Suite 145b, Fairbanks, AK	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on an off-site desk review of the laboratory's 2022 and 2023 American Proficiency Institute (API) proficiency testing (PT) records and a telephone interview with the laboratory testing personnel on April 10, 2023, it was determined that the laboratory failed to attain a score of at least eighty (80) percent of acceptable responses for Total Bilirubin in two (2) out of three (3) Chemistry testing events resulting in unsuccessful PT performance. See D2096
D2096	ROUTINE CHEMISTRY CFR(s): 493.841(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on an off-site desk review of the laboratory's 2022 and 2023 American Proficiency Institute (API) proficiency testing (PT) records, and a telephone interview with the testing person on April 10, 2023 it was determined that the laboratory failed to attain a score of at least eighty (80) percent of acceptable responses for Total Bilirubin in two (2) out of three (3) Chemistry events. Findings include: 1. Desk review of the laboratory's 2022 and 2023 API PT records revealed Total Bilirubin scores of less than eighty percent for the following chemistry events: 2022-2 score of 40% 2023-1 score of 60% 2. The testing person confirmed the laboratory was unsuccessful in the PT events listed above in a telephone interview on 4/10/2023 at 1:30 PM.